Brief: Inozyme Pharma Reports Positive Interim Data For INZ-701 And Key Program Updates

Inozyme Pharma

10/01/2025 13:25

Jan 10 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA ANNOUNCES POSITIVE INTERIM DATA FOR INZ-701
IN
INFANTS AND YOUNG CHILDREN WITH ENPP1 DEFICIENCY AND KEY PROGRAM
UPDATES
    * INOZYME PHARMA INC - NO RADIOGRAPHIC EVIDENCE OF RICKETS
IN
PATIENTS EVALUATED BEYOND ONE YEAR
    * INOZYME PHARMA INC - INZ-701 WELL-TOLERATED WITH NO
SERIOUS
ADVERSE EVENTS
    * INOZYME PHARMA INC - AIMS TO INITIATE ASPIRE TRIAL IN
EARLY 2026
    * INOZYME PHARMA INC - 80% OF INFANTS TREATED WITH INZ-701
SURVIVED BEYOND FIRST YEAR

Source text:  urn:newsml:reuters.com:*:nGNX5mTWw5
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))